Bright Minds Biosciences Inc Stock Price, News & Analysis

Bright Minds Biosciences (Nasdaq: DRUG) announced the departure of Chief Scientific Officer Dr. Alan Kozikowski, who played a crucial role in the company's early development. As the company transitions from drug discovery to clinical phases, Jan Torleif Pedersen, a current Board member, will serve as interim CSO. BMB-101, the company's leading drug candidate, shows promise in treating neuropsychiatric disorders. Bright Minds focuses on innovative treatments that minimize side effects compared to traditional psychedelic compounds.

Bright Minds Biosciences (Nasdaq: DRUG), a biotechnology firm, announced a symposium on May 19, 2022, focusing on Dravet Syndrome and therapeutic advancements. Key Opinion Leaders, including CEO Ian McDonald and experts from UCSF and Cook Children’s, will discuss BMB-101, the company's leading drug candidate for Dravet syndrome. Additionally, the company issued 100,000 restricted share units and 25,000 common shares to board members. BMB-101 is a selective 5-HT2C agonist, showing promise in treating neuropsychiatric disorders and addiction.

Bright Minds Biosciences announced a symposium for May 19, 2022, focusing on updates regarding BMB-101, its lead program for Dravet Syndrome treatment. Key speakers include CEO Ian McDonald and CMO Dr. Revati Shreeniwas. The event will feature expert discussions and a Q&A session. Additionally, the company has issued 60,000 RSUs related to consulting agreements and plans to issue 25,000 common shares, both subject to vesting and hold periods. Dravet Syndrome, affecting approximately 1:15,700 individuals in the U.S., represents a significant unmet medical need.

Bright Minds Biosciences (Nasdaq: DRUG) announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101, with no major toxicological findings observed. Conducted by ITR Laboratories Canada, the studies confirmed that BMB-101 was well tolerated in both mice and dogs at doses of up to 40 and 30 mg/kg/day, respectively. The results support the forthcoming first-in-human clinical trial anticipated in Q2 2022. Dr. Revati Shreeniwas noted the potential of BMB-101 as a treatment for Dravet Syndrome, highlighting a significant unmet need in this area.

Bright Minds Biosciences (NASDAQ: DRUG) announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:00 PM ET. The presentation will focus on the company's work in developing novel treatments for neuropsychiatric disorders, epilepsy, and pain, particularly BMB-101. This selective serotonin agonist shows promise in treating conditions like Dravet syndrome and mental health disorders. An archived version will be available on the company’s website for 90 days post-conference.

Bright Minds Biosciences (BMB) announced a virtual presentation by CEO Ian McDonald and CSO Alan Kozikowski at the H.C. Wainwright Bioconnect Conference on January 10, 2022, starting at 7:00am ET. The presentation will cover their innovative drug development targeting neuropsychiatric disorders and epilepsy. The company is focused on advancing BMB-101, a selective serotonin receptor agonist, showing potential in treating addiction and impulsive behaviors. A replay of the presentation will be available on their website for 90 days after the event.

Bright Minds Biosciences (BMB) announced CEO Ian McDonald will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021, at 3:00 PM ET. The conference will feature a webcast, with an archived replay available on the company's website for 90 days. Bright Minds is focused on developing innovative treatments for neuropsychiatric disorders, epilepsy, and pain. Its investigational drug BMB-101 shows promise in treating conditions like Dravet syndrome and mental health disorders by targeting serotonin receptors involving crucial neurotransmitter pathways.

Bright Minds Biosciences (BMBIF, DRUG) announced significant advancements in its 5-HT2A psychedelic drug discovery program. The company has synthesized hundreds of novel compounds and aims to announce its lead molecule by Q1 2022. Utilizing advanced drug design and preclinical modeling, Bright Minds aims to develop safer, more potent treatments for neuropsychiatric disorders, including depression and PTSD. The potential market for mental health drugs is projected to grow from $37 billion in 2020 to $59 billion by 2031, highlighting a significant commercial opportunity for the company.

Bright Minds Biosciences (BMB) announced its common stock will be listed on the Nasdaq Capital Market under the ticker symbol 'DRUG' starting November 8, 2021. This listing is seen as a milestone, aiming to enhance shareholder returns and market presence. The company is advancing its lead drug candidate, BMB-101, targeting Dravet syndrome, with first-in-human trials expected in H1 2022. BMB focuses on innovative treatments for neuropsychiatric disorders, leveraging serotonin agonists to tackle difficult-to-treat conditions.